Upling, a medical cannabis delivery app, plans to officially launch Bud-E, an AI-powered cannabis genetics tool designed to help patients identify cannabis strains best suited to their individual health needs.
Currently in beta testing, Bud-E leverages patient-reported outcomes, medical history, and optional genetic information to generate personalized strain recommendations using artificial intelligence. A full launch is planned for October.
“By combining personal health data, patient feedback, and genetic insights, our platform transforms cannabis from a trial-and-error process into one grounded in science,” said Colin Fraser, founder of Upling, the first Black-Owned delivery-focused cannabis app. “Whether someone is managing PTSD, chronic pain, or insomnia, this tool takes the guesswork out and brings a precision medicine approach to cannabis care.”
Bud-E will initially be available to medical cannabis patients in Upling’s Washington, D.C. and Maryland service areas, with plans to expand to adult-use customers in the future.
